Cellular immunotherapy for neuroblastoma: A review of current vaccine and adoptive T cell therapeutics

Current Pharmaceutical Design

Volumn 15, Issue 4, 2009, Pages 424-429

  Louis, C U ^a   Brenner, M K ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Adoptive T cell transfer; Chimeric antigen receptors; Immunotheraphy; Neuroblastoma; Vaccine trials

Indexed keywords

BCG VACCINE; CANCER VACCINE; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM3; GLYCOPROTEIN; INTERLEUKIN 2; LYMPHOTACTIN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG TARGETING; HIGH RISK PATIENT; HUMAN; INJECTION SITE INFLAMMATION; LYMPHOCYTIC INFILTRATION; MEDICAL DECISION MAKING; NATURAL KILLER CELL; NEURAL CREST; NEUROBLASTOMA; NEUROBLASTOMA CELL; PAIN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; IMMUNOTHERAPY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEUROBLASTOMA; T-LYMPHOCYTES;

EID: 64249106791     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315765     Document Type: Review

References (58)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-20.
2. Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 152-8.
3. Anderson JR, Coccia PF. Is more better? Dose intensity in neuroblastoma. J Clin Oncol 1991; 9: 902-4.
4. Shuster JJ, Cantor AB, McWilliams N, Pole JG, Castleberry RP, Marcus R, et al. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991; 9: 1045-9.
5. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-73.
6. De BB, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di ML, et al. Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-601.
7. Johnson E, Dean SM, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med 2007; 9: 1-21.
8. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-7.
9. Stephenson J. Reengineered monoclonal antibodies step up to the plate in cancer studies. JAMA 1995; 274: 1821-2.
10. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243-65.
11. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984; 44: 5914-20.
12. Cheung NK, Sondel PM. Neuroblastoma immunology and immunotherapy. In: Cohn S, Cheung NK, Eds. Neuroblastoma. Springer: Press 2005: 223-42.
13. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430-40.
14. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the antiganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992; 35: 199-204.
15. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A: 261-7.
16. Rousseau RF, Brenner MK. Vaccine therapies for pediatric malignancies. Cancer J 2005; 11: 331-9.
17. Verneris MR, Wagner JE. Recent developments in cell-based immune therapy for neuroblastoma. J Neuroimmune Pharmacol 2007; 2: 134-9.
18. Shilyansky J, Jacobs P, Doffek K, Sugg SL. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J Pediatr Surg 2007; 42: 54-61.
19. Pawelec G. Tumour escape: Antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53: 262-74.
20. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200: 1581-92.
21. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103: 1280-91.
22. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513-9.
23. Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 92: 1941-9.
24. Bowman LC, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998; 9: 1303-11.
25. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985; 135: 242-6
26. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, et al. Lymphotactin: A cytokine that represents a new class of chemokine. Science 1994; 266: 1395-9.
27. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-5.
28. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101: 1718-26
29. Wolfl M,, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005; 54: 400-6.
30. Soling A, Schurr P, Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999; 19: 2205-9.
31. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004; 1028: 69-80.
32. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma- related pediatric solid tumors. Int J Cancer 1996; 69: 375-80.
33. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998; 4: 2801-5.
34. Whelan JP, Chatten J, Lampson LA. HLA class I and beta 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res 1985; 45: 5976-83.
35. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13.
36. Eshhar Z. Tumor-specific T-bodies: Towards clinical application. Cancer Immunol Immunother 1997; 45: 131-6.
37. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
38. Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004; 6: 704-11.
39. d'Uscio C, Blaser K. Establishment of anti-human neuroblastom-aselective isotype-switch variants. J Immunol Methods 1992; 146: 63-70.
40. d'Uscio CH, Jungi TW, Blaser K. Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma. Br J Cancer 1991; 64: 445-50.
41. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15: 825-33.
42. Pule M, Savoldo B, Myers G, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in neuroblastoma patients. Nat Med 2008; [In press].
43. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
44. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-5.
45. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002; 159: 123-33.
46. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990; 75: 1564-7.
47. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 1999; 6: 300-4.
48. Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer 2003; 88: 1527-36.
49. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005; 228: 155-61.
50. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933-41.
51. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-802.
52. Bracci L, Moschella F, Sestili P, La S, V, Valentini M, Canini I, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13: 644-53.
53. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008; 180: 2089-98.
54. Haight AE, Bowman LC, Ng CY, Vanin EF, Davidoff AM. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med Pediatr Oncol 2000; 35: 712-5.
55. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007; 30: 227-33.
56. Dayan CM, Wraith DC. Preparing for first-in-man studies: The challenges for translational immunology post-TGN1412. Clin Exp Immunol 2008; 151(2): 231-4.
57. Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, et al. HIV-1 vaccine development: Tackling virus diversity with a multi-envelope cocktail. Front Biosci 2008; 13: 609-20.
58. Xia ZW, Zhong WW, Meyrowitz JS, Zhang ZL. The role of heme oxygenase-1 in T cell-mediated immunity: The all encompassing enzyme. Curr Pharm Des 2008; 14(5): 454-64.